Summary & Overview

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

DRG 180 includes inpatient stays for respiratory neoplasms with Major Complication or Comorbidity, covering complex malignant pulmonary conditions that require substantial hospital resources. This matters for inpatient reimbursement because assignment to this Diagnosis-Related Group increases Medicare payment to reflect higher clinical complexity and resource intensity.

Respiratory Neoplasms with Major Complication or ComorbidityDRG Respiratory Neoplasms with MCCDRG 180Diagnosis-Related GroupInpatient ReimbursementMedicareThoracic SurgeryOncologyPulmonology

DRG 180 Overview

DRG 180 covers hospital admissions for respiratory neoplasms with Major Complication or Comorbidity and typically includes primary malignant lung tumors or metastatic pulmonary malignancies with severe associated conditions. This Diagnosis-Related Group captures higher resource use driven by intensive medical management, complex surgical care, prolonged hospital stay, or significant concurrent illnesses. It matters for Medicare inpatient payment because cases assigned here receive higher reimbursement relative to less complicated respiratory neoplasm Diagnosis-Related Groups, reflecting greater expected costs. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus affect Medicare payment.

Clinical Trials

Trials evaluating novel systemic therapies or multimodality regimens for advanced respiratory neoplasms in hospitalized patients with major complications: these studies focus on patients with lung cancer or other primary respiratory malignancies who are experiencing acute, severe complications (eg, airway obstruction, hemoptysis, malignant pleural effusion, or treatment-related pneumonitis) that require inpatient care. The objective is to assess safety, dosing strategies, and short-term clinical responses of new systemic agents or combinations given in the acute-care setting or immediately post-procedure; results inform inpatient management algorithms and timing of oncologic therapy. This research is relevant to providers and payers because it addresses resource-intensive hospital stays, potential reductions in length of stay through effective acute control, and cost implications of delivering expensive systemic treatments during episodes classified under DRG 180.
Comparative effectiveness studies of urgent interventional procedures and supportive care approaches for complication control: these trials compare approaches such as bronchoscopic tumor debulking, stent placement, thoracentesis/pleurodesis for malignant effusions, or targeted radiotherapy versus conservative medical management in patients admitted with life‑threatening or function‑limiting complications of respiratory tumors. The patient population includes those whose primary reason for admission is a complication of the neoplasm rather than elective oncologic therapy, and the trials measure outcomes like symptom relief, complication recurrence, readmission rates, and peri‑procedural morbidity. Findings are directly applicable to clinicians deciding which acute interventions optimize patient outcomes and to payers evaluating comparative costs and downstream utilization associated with different inpatient procedural strategies under this DRG.
Observational and interventional studies of post-discharge outcomes, transitional care, and readmission reduction for high‑risk respiratory neoplasm admissions: these studies enroll patients discharged after an admission for respiratory cancer with major complications to test transitional care bundles, early outpatient follow‑up protocols, palliative care integration, or remote monitoring to prevent early readmission and manage symptom burden. The focus is on patients with complex comorbidity profiles and high risk of short‑term rehospitalization or post‑discharge mortality, measuring metrics such as 30‑ and 90‑day readmission, emergency visits, quality of life, and cost‑of‑care. This research matters to providers and payers because reducing avoidable readmissions and improving care transitions can improve patient outcomes and lower total episode costs associated with DRG 180 admissions.

Clinical Trials

Trials evaluating novel systemic therapies or multimodality regimens for advanced respiratory neoplasms in hospitalized patients with major complications: these studies focus on patients with lung cancer or other primary respiratory malignancies who are experiencing acute, severe complications (eg, airway obstruction, hemoptysis, malignant pleural effusion, or treatment-related pneumonitis) that require inpatient care. The objective is to assess safety, dosing strategies, and short-term clinical responses of new systemic agents or combinations given in the acute-care setting or immediately post-procedure; results inform inpatient management algorithms and timing of oncologic therapy. This research is relevant to providers and payers because it addresses resource-intensive hospital stays, potential reductions in length of stay through effective acute control, and cost implications of delivering expensive systemic treatments during episodes classified under DRG 180.
Comparative effectiveness studies of urgent interventional procedures and supportive care approaches for complication control: these trials compare approaches such as bronchoscopic tumor debulking, stent placement, thoracentesis/pleurodesis for malignant effusions, or targeted radiotherapy versus conservative medical management in patients admitted with life‑threatening or function‑limiting complications of respiratory tumors. The patient population includes those whose primary reason for admission is a complication of the neoplasm rather than elective oncologic therapy, and the trials measure outcomes like symptom relief, complication recurrence, readmission rates, and peri‑procedural morbidity. Findings are directly applicable to clinicians deciding which acute interventions optimize patient outcomes and to payers evaluating comparative costs and downstream utilization associated with different inpatient procedural strategies under this DRG.
Observational and interventional studies of post-discharge outcomes, transitional care, and readmission reduction for high‑risk respiratory neoplasm admissions: these studies enroll patients discharged after an admission for respiratory cancer with major complications to test transitional care bundles, early outpatient follow‑up protocols, palliative care integration, or remote monitoring to prevent early readmission and manage symptom burden. The focus is on patients with complex comorbidity profiles and high risk of short‑term rehospitalization or post‑discharge mortality, measuring metrics such as 30‑ and 90‑day readmission, emergency visits, quality of life, and cost‑of‑care. This research matters to providers and payers because reducing avoidable readmissions and improving care transitions can improve patient outcomes and lower total episode costs associated with DRG 180 admissions.

OpenPayer

Summary & Overview

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

DRG 180 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes